GU Cancers 2023 | Updates from ECHOS: real world outcomes from mCSPC treatment with docetaxel

Orazio Caffo, MD, Santa Chiara Hospital, Pisa, Italy, gives updates from ECHOS (NCT00309985). This multicenter observational study is collecting data on the real-world outcomes of approximately 1300 patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel. Dr Caffo published the first half of the results on the docetaxel population (n ≈ 900) last year and highlights the possibility to perform several analyses on this data log. This trial is also currently collecting data on enzalutamide, abiraterone, and apalutamide. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.